Combined hematologic parameters to optimize review criteria on XE-5000

Int J Lab Hematol. 2020 Apr;42(2):152-161. doi: 10.1111/ijlh.13131. Epub 2019 Dec 10.

Abstract

Introduction: Forty-one consensus review rules are presented to a large number of hematology laboratories worldwide, as suggested by the International Consensus Group for Hematology Review. Research on the review criteria has mainly focused on adjusting the threshold of each parameter to establish optimized criteria with better efficiency based on the consensus group criteria. This study aimed to optimize the review criteria by combining hematologic parameters on a Sysmex XE-5000 hematology analyzer (XE-5000).

Material and methods: A total of 662 nucleated red blood cell (NRBC) and 406 atypical lymphocyte cell (AL) flagged samples were used to establish hematologic parameters associated with NRBC and AL, respectively. Another set of 1423 optimization samples were used to validate the optimized criteria of NRBC and AL by combining associative hematologic parameters. The efficiency of each set of criteria was compared and optimized to obtain better efficiency, an acceptable slide review rate, and a low false-negative rate.

Results: In the optimization NRBC set combining triple parameters, compared with the default setting (P < .001), the slide review rate declined from 30.26% to 14.42%, and the efficiency increased from 75.65% to 91.02%. In the optimization AL set combining triple parameters, compared with the default setting (P < .001), the slide review rate declined from 40.60% to 11.80%, and the efficiency increased from 64.02% to 93.00%.

Conclusions: Based on the adjustment of Q-flag values combining associative hematologic parameters, the optimal criteria with a low false-negative rate not only might have a higher efficiency but also may significantly reduce the slide review rate.

Keywords: XE-5000; atypical lymphocyte cells; nucleated red blood cells; optimal review criteria; slide review rate.

Publication types

  • Randomized Controlled Trial
  • Validation Study

MeSH terms

  • Adult
  • Aged
  • Blood Cell Count / instrumentation
  • Erythroblasts*
  • Female
  • Humans
  • Lymphocytes*
  • Male
  • Middle Aged